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The effect of systemic adjuvant chemotherapy on local breast recurrence
in node positive breast cancer patients treated by lumpectomy without
radiation
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Summary A randomised trial has previously been repeated in which 437 women with node positive breast
cancer received either a 12-week chemohormonal regimen consisting of cyclophosphamide, methotrexate,
fluorouracil, vincristine, prednisone, adriamycin and tamoxifen or 36 weeks of CMFVP. The present analysis
concerns the local recurrence rates for the 122 lumpectomy patients who did not receive breast irradiation. The
cumulative rate of local breast recurrence was greater in the 12-week than the 36-week group, P = 0.02.
Similarly, in the lumpectomy patients, the cumulative rate of distant recurrence was greater in the 12-week
than the 36-week group, P = 0.04. In conclusion, our results suggest that adjuvant chemotherapy impacts on
local breast recurrence in a similar manner to other sites in Stage II breast cancer patients treated by
lumpectomy without radiation. Despite the use of a conventional 36-week adjuvant chemotherapy regimen, the
local breast recurrence rate was substantial.
In recent years, based on the results of clinical trials, breast
conserving surgery has increased in popularity as the primary
surgical management for patients with operable breast cancer
(Veronesi et al., 1981; Fisher et al., 1985; Fisher et al., 1989;
Hayward, 1977; Veronesi, 1985. In a trial from the Milan
Cancer Institute, 701 women with clinical Stage I or Stage II
breast cancer were randomised to either Halstead radical
mastectomy or quadrantectomy and axillary dissection plus
local irradiation to the breast (Veronesi et al., 1981). No
significant difference in survival was detected between the
treatment groups. The NSABP conducted trial B-06, in
which 1,843 women with Stage I or II breast cancer were
randomised to either modified radical mastectomy, lumpec-
tomy plus axillary dissection plus local breast irradiation, or
lumpectomy plus axillary dissection alone (Fisher et al., 1985,
1989). No difference was detected in terms of overall survival
among the three treatment groups. In this trial however,
lumpectomy patients who received the local breast irradiation
had a substantial reduction in local breast recurrence com-
pared to non-irradiated patients (39% to 10%) at 8 years of
follow-up.
Based on the results of this trial and some non-randomised
studies (Cale, 1985; Pierquin, 1985; Botnick, 1985, radiation
to the breast has become standard practice in women under-
going lumpectomy. We have previously reported the results
of a randomised trial in which women with Stage II breast
cancer received either a 12-week chemohormonal regimen or
36 weeks of adjuvant chemotherapy (Levine et al., 1990). The
12-week treatment was found to be inferior to the 36-week
treatment both in terms of recurrence and survival. In this
trial, women underwent mastectomy or lumpectomy prior to
being randomised to one of the two alternative forms of
adjuvant systemic therapy and no patients received post-
operative breast irradiation. Thus, this trial has provided us
with the opportunity to examine the effect of two different
chemotherapy regimens on local breast recurrence in women
who have undergone lumpectomy without breast irradiation.
Methods
A detailed description of the patient population, study
design, treatment regimens, criteria for outcome assessment
and details of patient follow-up have been previously
reported (Levine et al., 1990). Briefly, we studied patients
under the age of 70 years with histologically confirmed axil-
lary node-positive breast cancer who had undergone modified
radical mastectomy or lumpectomy plus axillary dissection.
The type of surgery was based on the referring surgeon's and
patient's preferences. Patients were excluded from the study if
they had residual tumour at the surgical margins of the
lumpectomy. Informed consent was obtained from eligible
patients before assignment to treatment.
The 12-week regimen consisted of cyclophosphamide
80 mg m-2 day-' orally for 8 weeks, methotrexate 35 mgm-2
and fluorouracil 500 mg m-2 both intravenously weekly for 8
weeks, vincristine mgm-2 weekly for 4 weeks and then
every second week prednisone 50mg orally for 10 days and
then tapered, adriamycin 20 mg m-2 weekly for weeks 9
through 12, and tamoxifen 10 mg orally twice daily through-
out (CMFVP + AT). The 36-week regimen consisted of
cyclophosphamide 80 mg m-2 day-' orally for 36 weeks,
methotrexate 28 mgm2 and fluorouracil 500 mgm2 both
intravenously weekly for 8 weeks and then every second
week, vincristine 1.4 mgm2 weekly for 4 weeks and then
monthly, and prednisone 30 mgm2 orally for 10 days and
then tapered.
All local breast recurrences were confirmed histologically.
Distant recurrence was designed as any recurrence other than
a recurrence in the breast in which the original tumour had
been removed by lumpectomy.
Statistical analysis
The outcomes of cumulative local breast recurrence, distant
disease-free survival and overall survival were summarised as
survival curves using the Kaplan-Meier method (Kaplan,
1958). The survival curves of treatment groups were com-
pared using the Mantel-Cox test (Mantel, 1966). When
comparing treatment effects, the Cox proportional hazards
model was used to adjust for the influence of various prog-
nostic factors including age, number of positive nodes,
menopausal status, oestrogen receptor level, progesterone
receptor level, and tumour size (Cox, 1972). Tests for linear
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trend in proportions used Cochran's regression method
(Cochran, 1954). All quoted tests of statistical significance
are two-tailed.
Results
The trial commenced recruitment in November 1983 and the
last patient was entered in May 1987. The median follow-up
at the present time is 54 months. One hundred and twenty-
two patients underwent lumpectomy and 315 modified radical
mastectomy. During the first 14 months of the trial
(November 1983 to December 1984), 22 of the 123 patients
(18%) entered underwent lumpectomy. In 1985, 30 of 127
patients (24%) entered underwent lumpectomy. During the
last 17 months of the trial (January 1986 to May 1987), the
proportion of patients who underwent lumpectomy increased
further to 70 out of 187 (37%). This increase in the rate of
lumpectomy over the trial recruitment period is statistically
significant, P = 0.0001.
Comparison of12-week and 36-week groups
Of the patients who underwent lumpectomy, 62 were ran-
domly allocated to the shorter 12-week chemohormonal
therapy and 60 to the more conventional 36-week
chemotherapy. Thirty-eight patients in the 12-week lumpec-
tomy group experienced a recurrence of their breast cancer
compared to 22 patients in the 36-week lumpectomy group.
Recurrence rates, both local and distant, for the lumpectomy
patients are given in Table I. None of the patients who
underwent lumpectomy experienced a recurrence in the
regional nodes. Thus, 24 of the 62 patients (39%) in the
12-week group who underwent lumpectomy experienced a
local breast recurrence and in 22 this was the first event. In
comparison, 14 patients (23%) in the 36-week lumpectomy
group had a local breast recurrence; in 11 this was the first
event (see Table I). The cumulative rate of local breast
recurrence as a first event was greater in the 12-week than
than the 36-week group, P = 0.02 (Figure 1). When the Cox
regression analysis was performed, which adjusted for any
imbalances in baseline prognostic factors, the risk ratio for a
local event in the 12-week compared to the 36-week group
was 2.6 (P = 0.02).
For the lumpectomy patients, the cumulative rate of non-
local breast recurrence (distant) was greater in the 12-week
group than the 36-week group, 50% vs 33% respectively, at
48 months, P = 0.04. In the Cox regression analysis the risk
ratio for a distant event in the 12-week group compared to
the 36-week group was 1.4 (P = 0.02), and was of a similar
order of magnitude in both the lumpectomy (1.9) and
mastectomy (1.4) patients.
For lumpectomy -patients, the overall survival in the 36-
week group was also greater than the 12-week group, but did
not reach conventional levels of statistical significance,
P = 0.29 (Figure 2). In the Cox analysis the risk ratio for a
fatal event in the 12-week group compared to the 36-week
group was 1.4 (P = 0.10), and was comparable in both the
lumpectomy (1.6) and mastectomy (1.4) patients. The overall
Table I Distribution of recurrences
Treatmentgroup
Recurrencea 12-week (n = 62) 36-week (n = 60)
Local breast only 11 (29%) 5 (23%)
Simultaneous (breast and 1 (3%) 3 (14%)
distant)
Sequential (breast first) 11 (29%) 6(27%)
Sequential (distantfirst) 1(3%) 0(0%)
Distant only 14(37%) 8 (36%)
Regional nodes 0 0
Total 38 (100%) 22(100%)
aNumber ofpatients.
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Figure 1 The cumulative rate of local breast recurrence as a first
event in the 12-week group ( . ) compared to the 36-week
group ( ).
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Figure 2 For lumpectomy patients, survival of 36-week group
( ~) compared to 12-week group ( ).
survival at 48 months for the lumpectomy group was 78%
compared to 72% for mastectomy patients, P = 0.25.
Analysis using all local recurrences rather than only those
local recurrences which were first events showed similar
results.
Management oflocal breast recurrences
The study protocol did not specify a standard form of man-
agement once a lumpectomy patient experienced a local breast
recurrence. The management of a local recurrence in such
patients is presented in Table II. Twenty-two (57%) of the
patients went on to mastectomy, and eight (22%) had
another lumpectomy. In four patients (11%), breast irradia-
Table II Management of local breast recurrence
Treatment Patient no. (%)
Mastectomy 22 (57%)
Lumpectomy 8 (22%)
Radiation alone 4 (11%)
Systemic therapy alone 2 (5%)
Systemic therapy + radiation 2 (5%)
n V L
0
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tion was the only form of management. Two patients under-
went systemic (tamoxifen or chemotherapy) therapy plus
irradiation to the breast and in two patients systemic therapy
was administered alone.
Discussion
Results from the NSABP B-06 trial have shown that local
breast irradiation in Stage I and II breast cancer patients
who have undergone lumpectomy reduces the risk of local
breast recurrence but does not impact on overall survival
(Fisher et al., 1985, 1989). Apart from this study, however,
there is not extensive published information from randomised
trials on the experience of Stage II breast cancer patients who
have undergone lumpectomy and received adjuvant chemo-
therapy, but no local breast irradiation. In our randomised
trial, comparing 12 weeks with 36 weeks of adjuvant
chemotherapy, women with Stage II breast cancer had under-
gone either lumpectomy or mastectomy, but received no
radiation. The 12-week regimen was inferior to the 36-week
regimen in terms of relapse-free survival and overall survival
(Levine et al., 1990). The study also provided us with the
opportunity to examine the impact of the two different
regimens on the rates of local breast recurrence in lumpec-
tomy patients.
The results of this analysis show that the rate of local
breast recurrence, either as a first event or at any time, was
greater in the 12-week patient group compared to the 36-
week group. In addition for lumpectomy patients, the
12-week chemohormonal regimen was ineffective compared
to 36 weeks of chemotherapy in controlling distant recur-
rence. Thus, in terms of the biology of breast cancer, the
differing local recurrence rates between the two regimens
provides evidence that adjuvant chemotherapy itself can
impact on the rate of local breast recurrence in lumpectomy
patients, in a similar manner to its effect on recurrence in
other sites. The two treatment regimens in the trial differed in
both drug content and duration. Possible explanations for
the observed inferiority of the 12-week treatment for both
local and distant recurrences were its shorter duration and/or
a negative interaction of tamoxifen on the chemotherapy
(Levine et al., 1990).
The overall absolute rate of local breast recurrence (31%)
in our lumpectomy patients was considerable at a median
follow-up of 54 months. In the NSABP B-06 study, in the
Stage II women, the rate of local breast recurrence was 6%
in the irradiated group compared to 43% in the unirradiated
group at 8 years of follow-up (Fisher et al., 1989). All these
Stage II patients received chemotherapy. Thus, although
there are limitations in comparing between studies, our
observed local breast recurrence rate is consistent with that in
B-06. In addition, in the NSABP study the rate of local
recurrence in the node negative patients who received radia-
tion was 12%. The lower recurrence rate in the node positive
irradiated patients compared to the node negative irradiated.
patients was attributed to a possible synergistic effect
between chemotherapy and radiation (Fisher et al., 1989).
When the results of B-06 were published, recruitment to
our trial was well along the way. Since no difference in
overall survival was reported in B-06 and because of concern
for interactions between radiation and chemotherapy, the
study investigators in our trial decided not to introduce local
breast irradiation.
In conclusion, our results suggest that adjuvant chemo-
therapy impacts on local breast recurrence in Stage II breast
cancer patients treated by lumpectomy without radiation.
Despite the use of a conventional 36-week adjuvant
chemotherapy regimen, the local breast recurrence rate was
substantial. It is possible that with improved adjuvant
regimens, local recurrence in lumpectomy breasts may
diminish, thus obviating the need for local breast irradiation.
This, however, awaits the results of future trials and mean-
while local breast irradiation should continue as standard
treatment for women with Stage II breast cancer who have
undergone lumpectomy.
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